ONCE Spark Therapeutics Inc.

85.82
+2.99  (4%)
Previous Close 82.83
Open 82.67
Price To book 13.75
Market Cap 3136393940
Shares 36,546,189
Volume 442,752
Short Ratio 6.65
Av. Daily Volume 536,300

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171089246
  2. CT ORDER - Confidential treatment order 171089239
  3. CT ORDER - Confidential treatment order 171089202
  4. CT ORDER - Confidential treatment order 171089188
  5. CT ORDER - Confidential treatment order 171089166

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 promising initial data released from first two patients - August 2, 2017. 11% and 14% Factor VIII.
SPK-8011
Hemophilia A
Phase 1/2 updated data released July 10, 2017. 99% fall in infusion rate.
SPK-9001
Hemophilia B
Phase 1/2 dosing commenced 1Q 2015. Initial data released May 9, 2017.
SPK-7001 (SPK-CHM)
Choroideremia
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017.
Voretigene neparvovec (SPK-RPE65)
Inherited retinal dystrophies

Latest News

  1. Spark Therapeutics Enters into Licensing Agreement with Genethon
  2. RBC Launches Biotech Sector Coverage Amid 'An Innovation Revolution'
  3. ETFs with exposure to Spark Therapeutics, Inc. : September 13, 2017
  4. See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
  5. Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
  6. Breaking Down Barclays' New Bullish Calls On Biotech
  7. 3 Stocks Your Children Will Brag About Someday
  8. How investors should play gene-therapy stocks
  9. Here's Why Spark Therapeutics Inc. Surged 23.5% in August
  10. Spark Therapeutics Is Ready to Catch Fire
  11. Spark Therapeutics Announces Publication of Study Confirming Novel Test’s Validity, Reliability and Ability to Detect Change in Functional Vision
  12. Spark Therapeutics to Participate in Multiple Conferences in September
  13. Edited Transcript of ONCE earnings conference call or presentation 2-Aug-17 12:30pm GMT
  14. Spark Therapeutics Recognized as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
  15. CHOP spinout Spark completes $402M stock sale
  16. IHS Markit Score downgrades Spark Therapeutics Inc to 24 out of 100, ranking positively in only one out of three available IHS Markit categories.

SEC Filings

  1. CT ORDER - Confidential treatment order 171089246
  2. CT ORDER - Confidential treatment order 171089239
  3. CT ORDER - Confidential treatment order 171089202
  4. CT ORDER - Confidential treatment order 171089188
  5. CT ORDER - Confidential treatment order 171089166
  6. CT ORDER - Confidential treatment order 171029082
  7. 8-K - Current report 171007018
  8. 424B2 - Prospectus [Rule 424(b)(2)] 171007013
  9. 424B5 - Prospectus [Rule 424(b)(5)] 171002701
  10. FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses 171001286